← Back to Search

Antisense Oligonucleotide

Casimersen + Golodirsen for Duchenne Muscular Dystrophy (ESSENCE Trial)

Phase 3
Waitlist Available
Research Sponsored by Sarepta Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Stable pulmonary function: forced vital capacity (FVC) ≥50% predicted
Mean 6MWT ≥300 meters and ≤450 meters
Must not have
Previous treatment with SMT C1100 within 1 week prior to Week 1 and previous treatment with PRO045 (BMN 045), PRO053 (BMN 053), or PRO051 (BMN 051) within 24 weeks prior to Week 1
Major surgery within 3 months prior to Week 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 96, week 144
Awards & highlights
Pivotal Trial

Summary

This trial will test two drugs, casimersen and golodirsen, to see if they are effective in treating Duchenne Muscular Dystrophy in patients with specific gene mutations.

Who is the study for?
This trial is for individuals with Duchenne Muscular Dystrophy (DMD) who have specific genetic deletions treatable by skipping exon 45 or exon 53. Participants must be on a stable dose of corticosteroids, have certain muscle function, and maintain a specific range in the 6-minute walk test. They should not have had gene therapy or other recent experimental treatments.
What is being tested?
The study tests the effectiveness of two drugs, SRP-4045 (casimersen) and SRP-4053 (golodirsen), against a placebo in improving DMD symptoms related to specific genetic mutations. The goal is to see if these drugs can help skip over faulty parts of the gene.
What are the potential side effects?
While side effects are not detailed here, similar trials may involve risks like injection site reactions, potential kidney damage, blood changes, and possible allergic reactions. Each patient's experience with side effects could vary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lung function is at least half of what is expected for someone my age and size.
Select...
I can walk between 300 to 450 meters in 6 minutes.
Select...
Both of my biceps or two other upper body muscles are healthy.
Select...
My DMD is treatable with exon 45 or 53 skipping.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been treated with SMT C1100 recently and PRO045, PRO053, or PRO051 in the last 6 months.
Select...
I have not had major surgery in the last 3 months.
Select...
I have never undergone gene therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 96, week 144
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 96, week 144 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change From Baseline in the NSAA Total Score at Week 96 and Week 144
Participant's Ability to Rise Independently From the Floor, as indicated by a North Star Ambulatory Assessment (NSAA) Subscore

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: SRP-4053Experimental Treatment1 Intervention
Participants amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
Group II: SRP-4045Experimental Treatment1 Intervention
Participants amenable to exon 45 skipping will receive SRP-4045 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
Group III: Placebo followed by SRP-4045 or SRP-4053Placebo Group3 Interventions
Participants amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SRP-4045
2015
Completed Phase 1
~20
SRP-4053
2015
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Sarepta Therapeutics, Inc.Lead Sponsor
52 Previous Clinical Trials
33,724 Total Patients Enrolled
Medical DirectorStudy DirectorSarepta Therapeutics, Inc.
2,866 Previous Clinical Trials
8,082,354 Total Patients Enrolled

Media Library

SRP-4045 (Antisense Oligonucleotide) Clinical Trial Eligibility Overview. Trial Name: NCT02500381 — Phase 3
Duchenne Muscular Dystrophy Research Study Groups: SRP-4053, SRP-4045, Placebo followed by SRP-4045 or SRP-4053
Duchenne Muscular Dystrophy Clinical Trial 2023: SRP-4045 Highlights & Side Effects. Trial Name: NCT02500381 — Phase 3
SRP-4045 (Antisense Oligonucleotide) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02500381 — Phase 3
~0 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top